Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon vs Glucagon for severe hypoglycemia in Asian adults with T1D and Japanese adolescents
NCT06588504Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2024
- Primary completion
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dasiglucagon in hypoglycemia (3 cohorts), sponsored by Novo Nordisk. Primary endpoint: Time to plasma glucose recovery. Started Sep 2024; status: completed.
02
Drugs
dasiglucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT06588504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588504.